The Burden of Short-Acting β2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.

Fabiano Di MarcoMariella D'AmatoFrancesco P LombardoClaudio MichelettoFranca HeimanValeria PegoraroSilvia BoarinoGiandomenico MannaFrancesca MastromauroSimona SpennatoAlberto Papi

Published in: Advances in therapy (2021)

SABA overuse is common in Italy, with a share of consumption not regulated by medical prescriptions. Because SABA overuse increases exacerbation risk, changes to national guidelines should be encouraged to ensure implementation of global recommendations.

Keyphrases

quality improvement
chronic obstructive pulmonary disease
clinical practice
healthcare
lung function
primary care
allergic rhinitis
risk factors
intensive care unit
acute respiratory distress syndrome